Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2025. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of August 31, 2025, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (as of Aug 31, 2025) | 4,315,396,096 |
| Share Price | 31 1/4 pence each |
| Treasury Shares | 244,408,471 |
| Total Voting Rights | 4,070,987,625 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of share capital and voting rights as of the specified date.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. Its sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Important Facts for Investors
- Voting Rights Denominator: Shareholders must use 4,070,987,625 as the total number of voting rights when determining if they are required to notify their interest or changes in interest under FCA rules.
- Treasury Shares: Approximately 244.4 million shares are held in Treasury and do not carry voting rights.
- Contact for Notifications: Notifications regarding share interests should be sent to company.secretary@gsk.com.